噬菌体疗法未被利用的机会。 - Suppr

Unexploited opportunities for phage therapy.

作者信息

Oliveira Hugo, Sillankorva Sanna, Merabishvili Maia, Kluskens Leon D, Azeredo Joana

机构信息

Laboratório de Investigação em Biofilmes Rosário Oliveira, Centre of Biological Engineering, University of Minho Braga, Portugal.

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital Brussels, Belgium.

出版信息

Front Pharmacol. 2015 Sep 7;6:180. doi: 10.3389/fphar.2015.00180. eCollection 2015.

DOI:10.3389/fphar.2015.00180

PMID:26441644

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4561355/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba1/4561355/87229c7de119/fphar-06-00180-g0001.jpg

相似文献

Unexploited opportunities for phage therapy.

Front Pharmacol. 2015 Sep 7;6:180. doi: 10.3389/fphar.2015.00180. eCollection 2015.

Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.

Microb Pathog. 2024 Jan;186:106467. doi: 10.1016/j.micpath.2023.106467. Epub 2023 Nov 28.

Basic Guidelines for Bacteriophage Isolation and Characterization.

Recent Pat Biotechnol. 2023;17(4):312-331. doi: 10.2174/1872208317666221017094715.

Molecular Basis for Lytic Bacteriophage Resistance in Enterococci.

mBio. 2016 Aug 30;7(4):e01304-16. doi: 10.1128/mBio.01304-16.

Isolation of lytic bacteriophage against Vibrio harveyi.

J Appl Microbiol. 2010 May;108(5):1744-50. doi: 10.1111/j.1365-2672.2009.04578.x. Epub 2009 Oct 7.

Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations.

Pharmacotherapy. 2020 Feb;40(2):153-168. doi: 10.1002/phar.2358. Epub 2020 Jan 13.

Characterization of an Bacteriophage vB_EfaM_LG1 and Its Synergistic Effect With Antibiotic.

Front Cell Infect Microbiol. 2021 Jul 16;11:698807. doi: 10.3389/fcimb.2021.698807. eCollection 2021.

Bacteriophages for ESKAPE: role in pathogenicity and measures of control.

Expert Rev Anti Infect Ther. 2021 Jul;19(7):845-865. doi: 10.1080/14787210.2021.1858800. Epub 2021 Jan 8.

Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future.

Folia Microbiol (Praha). 2023 Jun;68(3):357-368. doi: 10.1007/s12223-023-01046-y. Epub 2023 Apr 10.

Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities.

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00993-20.

引用本文的文献

Isolation and characterization of a novel bacteriophage PUTH1 active against Pseudomonas aeruginosa.

Virol J. 2025 Jul 19;22(1):248. doi: 10.1186/s12985-025-02859-8.

Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.

Mol Biotechnol. 2025 Jul 9. doi: 10.1007/s12033-025-01466-w.

The Potential of Bacteriophage-Antibiotic Combination Therapy in Treating Infections with Multidrug-Resistant Bacteria.

Antibiotics (Basel). 2023 Aug 17;12(8):1329. doi: 10.3390/antibiotics12081329.

Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against .

Viruses. 2023 Apr 25;15(5):1042. doi: 10.3390/v15051042.

Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens.

Bioeng Transl Med. 2022 Aug 6;8(2):e10381. doi: 10.1002/btm2.10381. eCollection 2023 Mar.

Advancements in bacteriophage therapies and delivery for bacterial infection.

Mater Adv. 2023 Jan 31;4(5):1249-1257. doi: 10.1039/d2ma00980c. eCollection 2023 Mar 6.

Neat Science in a Messy World: The Global Impact of Human Behavior on Phage Therapy, Past and Present.

Phage (New Rochelle). 2020 Mar 1;1(1):16-22. doi: 10.1089/phage.2019.0002. Epub 2020 Feb 25.

Wastewater as a fertility source for novel bacteriophages against multi-drug resistant bacteria.

Saudi J Biol Sci. 2021 Aug;28(8):4358-4364. doi: 10.1016/j.sjbs.2021.04.025. Epub 2021 Apr 16.

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.

Drugs. 2021 Jul;81(10):1153-1169. doi: 10.1007/s40265-021-01530-0. Epub 2021 Jun 7.

J Glob Health. 2020 Dec;10(2):020504. doi: 10.7189/jogh.10.020504.

本文引用的文献

Phage neutralization by sera of patients receiving phage therapy.

Viral Immunol. 2014 Aug;27(6):295-304. doi: 10.1089/vim.2013.0128. Epub 2014 Jun 3.

Call for a dedicated European legal framework for bacteriophage therapy.

Arch Immunol Ther Exp (Warsz). 2014 Apr;62(2):117-29. doi: 10.1007/s00005-014-0269-y. Epub 2014 Feb 6.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053.

Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2183. doi: 10.1371/journal.pntd.0002183. Print 2013.

Bacteriophages and their role in food safety.

Int J Microbiol. 2012;2012:863945. doi: 10.1155/2012/863945. Epub 2012 Dec 18.

Polymer nanogels: a versatile nanoscopic drug delivery platform.

Adv Drug Deliv Rev. 2012 Jun 15;64(9):836-51. doi: 10.1016/j.addr.2012.02.002. Epub 2012 Feb 10.

Pros and cons of phage therapy.

Bacteriophage. 2011 Mar;1(2):111-114. doi: 10.4161/bact.1.2.14590.

Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.

J Pharm Pharmacol. 2011 Oct;63(10):1253-64. doi: 10.1111/j.2042-7158.2011.01324.x. Epub 2011 Jul 6.

The phage therapy paradigm: prêt-à-porter or sur-mesure?

Pharm Res. 2011 Apr;28(4):934-7. doi: 10.1007/s11095-010-0313-5. Epub 2010 Nov 10.

The clinical consequences of antimicrobial resistance.

Curr Opin Microbiol. 2009 Oct;12(5):476-81. doi: 10.1016/j.mib.2009.08.001. Epub 2009 Aug 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Unexploited opportunities for phage therapy.

Front Pharmacol. 2015 Sep 7;6:180. doi: 10.3389/fphar.2015.00180. eCollection 2015.

Bacteriophage therapy against ESKAPE bacterial pathogens: Current status, strategies, challenges, and future scope.

Microb Pathog. 2024 Jan;186:106467. doi: 10.1016/j.micpath.2023.106467. Epub 2023 Nov 28.

Basic Guidelines for Bacteriophage Isolation and Characterization.

Recent Pat Biotechnol. 2023;17(4):312-331. doi: 10.2174/1872208317666221017094715.

Molecular Basis for Lytic Bacteriophage Resistance in Enterococci.

mBio. 2016 Aug 30;7(4):e01304-16. doi: 10.1128/mBio.01304-16.

Isolation of lytic bacteriophage against Vibrio harveyi.

J Appl Microbiol. 2010 May;108(5):1744-50. doi: 10.1111/j.1365-2672.2009.04578.x. Epub 2009 Oct 7.

Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations.

Pharmacotherapy. 2020 Feb;40(2):153-168. doi: 10.1002/phar.2358. Epub 2020 Jan 13.

Characterization of an Bacteriophage vB_EfaM_LG1 and Its Synergistic Effect With Antibiotic.

Front Cell Infect Microbiol. 2021 Jul 16;11:698807. doi: 10.3389/fcimb.2021.698807. eCollection 2021.

Bacteriophages for ESKAPE: role in pathogenicity and measures of control.

Expert Rev Anti Infect Ther. 2021 Jul;19(7):845-865. doi: 10.1080/14787210.2021.1858800. Epub 2021 Jan 8.

Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future.

Folia Microbiol (Praha). 2023 Jun;68(3):357-368. doi: 10.1007/s12223-023-01046-y. Epub 2023 Apr 10.

Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities.

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00993-20.

引用本文的文献

Isolation and characterization of a novel bacteriophage PUTH1 active against Pseudomonas aeruginosa.

Virol J. 2025 Jul 19;22(1):248. doi: 10.1186/s12985-025-02859-8.

Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.

Mol Biotechnol. 2025 Jul 9. doi: 10.1007/s12033-025-01466-w.

The Potential of Bacteriophage-Antibiotic Combination Therapy in Treating Infections with Multidrug-Resistant Bacteria.

Antibiotics (Basel). 2023 Aug 17;12(8):1329. doi: 10.3390/antibiotics12081329.

Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against .

Viruses. 2023 Apr 25;15(5):1042. doi: 10.3390/v15051042.

Phage engineering and phage-assisted CRISPR-Cas delivery to combat multidrug-resistant pathogens.

Bioeng Transl Med. 2022 Aug 6;8(2):e10381. doi: 10.1002/btm2.10381. eCollection 2023 Mar.

Advancements in bacteriophage therapies and delivery for bacterial infection.

Mater Adv. 2023 Jan 31;4(5):1249-1257. doi: 10.1039/d2ma00980c. eCollection 2023 Mar 6.

Neat Science in a Messy World: The Global Impact of Human Behavior on Phage Therapy, Past and Present.

Phage (New Rochelle). 2020 Mar 1;1(1):16-22. doi: 10.1089/phage.2019.0002. Epub 2020 Feb 25.

Wastewater as a fertility source for novel bacteriophages against multi-drug resistant bacteria.

Saudi J Biol Sci. 2021 Aug;28(8):4358-4364. doi: 10.1016/j.sjbs.2021.04.025. Epub 2021 Apr 16.

Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions.

Drugs. 2021 Jul;81(10):1153-1169. doi: 10.1007/s40265-021-01530-0. Epub 2021 Jun 7.

J Glob Health. 2020 Dec;10(2):020504. doi: 10.7189/jogh.10.020504.

本文引用的文献

Phage neutralization by sera of patients receiving phage therapy.

Viral Immunol. 2014 Aug;27(6):295-304. doi: 10.1089/vim.2013.0128. Epub 2014 Jun 3.

Call for a dedicated European legal framework for bacteriophage therapy.

Arch Immunol Ther Exp (Warsz). 2014 Apr;62(2):117-29. doi: 10.1007/s00005-014-0269-y. Epub 2014 Feb 6.

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053.

Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2183. doi: 10.1371/journal.pntd.0002183. Print 2013.

Bacteriophages and their role in food safety.

Int J Microbiol. 2012;2012:863945. doi: 10.1155/2012/863945. Epub 2012 Dec 18.

Polymer nanogels: a versatile nanoscopic drug delivery platform.

Adv Drug Deliv Rev. 2012 Jun 15;64(9):836-51. doi: 10.1016/j.addr.2012.02.002. Epub 2012 Feb 10.

Pros and cons of phage therapy.

Bacteriophage. 2011 Mar;1(2):111-114. doi: 10.4161/bact.1.2.14590.

Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.

J Pharm Pharmacol. 2011 Oct;63(10):1253-64. doi: 10.1111/j.2042-7158.2011.01324.x. Epub 2011 Jul 6.

The phage therapy paradigm: prêt-à-porter or sur-mesure?

Pharm Res. 2011 Apr;28(4):934-7. doi: 10.1007/s11095-010-0313-5. Epub 2010 Nov 10.

The clinical consequences of antimicrobial resistance.

Curr Opin Microbiol. 2009 Oct;12(5):476-81. doi: 10.1016/j.mib.2009.08.001. Epub 2009 Aug 27.

Unexploited opportunities for phage therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Unexploited opportunities for phage therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献